Positive results with Revolade™ and Arzerra™ for difficult-to-treat blood disorders

EAN 2026: Positive trial data for cemdisiran underscores potential for use in generalized MG, says GlobalData

On June 30, at the 12th Congress of the European Academy of Neurology (EAN) 2026, Regeneron announced the results from an additional analysi

EMA begins phased review of daraxonrasib for metastatic pancreatic cancer treatment

Phased review has started to accelerate assessment of medicine with potential to address high unmet medical need

<![CDATA[EMA’s Review of Daraxonrasib in PDAC Accelerated Under Phased Review Process]]>

STAT+: FDA approves Vera Therapeutics kidney disease treatment

The FDA approved a new medicine from the biotech company Vera Therapeutics for patients with a type of chronic autoimmune kidney disease.

Anixa Biosciences Aktie: Höchste Lira-cel-Dosis erreicht

Ein Meilenstein in der Krebsforschung: Anixa Biosciences hat den fünften Patienten in die höchste Dosiskohorte seiner CAR-T-Zelltherapie auf

Four JAK Inhibitors Show Positive Late-Stage Trial Results for Axial Spondyloarthritis Treatment

Data from phase 3 studies with filgotinib, gecacitinib, and ivarmacitinib and a phase 4 study of tofacitinib in early disease are reported.